C-C chemokine receptor type 1 (CCR1) (CCR1)

C-C chemokine receptor type 1 (CCR1) is a G protein-coupled receptor (GPCR) that plays a pivotal role in the immune system by mediating the migration of leukocytes to sites of inflammation [UniProt: P51675]. In rats, CCR1 is expressed on various immune cells, including monocytes, macrophages, and T lymphocytes, and it responds to several CC chemokines such as CCL3 (MIP-1 alpha), CCL5 (RANTES), and CCL7 (MCP-3) [NCBI Gene: 25542]. Upon ligand binding, CCR1 initiates intracellular signaling cascades, primarily through Gi proteins, leading to calcium mobilization and actin polymerization necessary for chemotaxis [PubMed: 11544308]. This receptor is heavily implicated in the pathogenesis of chronic inflammatory and autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, and chronic kidney disease, where it facilitates excessive leukocyte infiltration and tissue damage [PubMed: 12140600]. Consequently, CCR1 has been a major target for drug development, with several small-molecule antagonists like BX471 being extensively studied in rat models to demonstrate efficacy in reducing inflammation and fibrosis [PubMed: 11854455]. Despite its potential, therapeutic success in humans has been limited by the redundancy of the chemokine system and significant differences in ligand affinity between human and rodent orthologs [PubMed: 15652214]. In rat-specific research, CCR1 is often used to study the progression of renal interstitial fibrosis and the mechanisms of transplant rejection [PubMed: 12140600]. The receptor's role in cancer metastasis, particularly in the bone and liver, has also been explored using rat models [PubMed: 16432181].

Other names

C-C CKR-1CC-CKR-1CCR-1MIP-1 alpha receptorRANTES receptorCD191Cmkbr1

CCR1 antagonists bind to the receptor and competitively inhibit the binding of pro-inflammatory chemokines such as CCL3 and CCL5, thereby preventing the recruitment and activation of leukocytes at sites of inflammation [PubMed: 11854455].